electroCore Inc.
| NASDAQ: ECOR | Healthcare / Medical Devices & Instruments / USA |
| 1.76 | -0.0285 | -1.59% | Vol 279.48K | 1Y Perf 59.34% |
| Apr 19th, 2021 13:50 DELAYED |
| BID | 1.76 | ASK | 1.77 | ||
| Open | 1.87 | Previous Close | 1.79 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 3.60 | Analyst Rating | Moderate Buy 1.67 | |
| Potential % | 105.70 | Finscreener Ranking | ★★★★ 53.94 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.22 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★ 61.60 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 85.39M | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 34.67 | Earnings Date | 13th May 2021 |
Today's Price Range 1.721.88 | 52W Range 0.77003.63 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.67% | ||
| 1 Month | -17.89% | ||
| 3 Months | 1.13% | ||
| 6 Months | 0.56% | ||
| 1 Year | 59.34% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 291.26 | |||
ROE last 12 Months | -95.14 | |||
ROA (5Y Avg) | -72.91 | |||
ROA last 12 Months | -67.05 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -77.86 | |||
Return on invested Capital Q | -21.87 | |||
Return on invested Capital Y | -90.25 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 6.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.30 | ||||
| 4.34 | ||||
| 32.12 | ||||
| - | ||||
| -8.50 | ||||
| -0.52 | ||||
| 4.34 | ||||
| 0.47 | ||||
| 80.23M | ||||
| Forward PE | -5.93 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.90 | ||||
| 4.30 | ||||
| 0.08 | ||||
| 0.13 | ||||
| - | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 50.30 | ||||
| -819.30 | ||||
| -807.40 | ||||
| -3 772.00 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.76M | ||||
| 0.06 | ||||
| 71.52 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.10 | -0.14 | -40.00 |
| Q03 2020 | -0.12 | -0.10 | 16.67 |
| Q02 2020 | -0.17 | -0.13 | 23.53 |
| Q01 2020 | -0.25 | -0.26 | -4.00 |
| Q04 2019 | -0.30 | -0.29 | 3.33 |
| Q03 2019 | - | -0.36 | - |
| Q02 2019 | - | -0.41 | - |
| Q01 2019 | - | -0.47 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.12 | -50.00 | Negative |
| 6/2021 QR | -0.12 | -50.00 | Negative |
| 12/2021 FY | -0.43 | -13.16 | Negative |
| 12/2022 FY | -0.33 | -13.79 | Negative |
| Next Report Date | 13th May 2021 |
| Estimated EPS Next Report | -0.12 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 279.48K |
| Shares Outstanding | 48.48M |
| Trades Count | 1.44K |
| Dollar Volume | 2.40M |
| Avg. Volume | 3.77M |
| Avg. Weekly Volume | 648.47K |
| Avg. Monthly Volume | 1.09M |
| Avg. Quarterly Volume | 4.33M |
electroCore Inc. (NASDAQ: ECOR) stock closed at 1.79 per share at the end of the most recent trading day (a 1.7% change compared to the prior day closing price) with a volume of 1.16M shares and market capitalization of 85.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 51 people. electroCore Inc. CEO is Daniel S. Goldberger.
The one-year performance of electroCore Inc. stock is 59.34%, while year-to-date (YTD) performance is 14.74%. ECOR stock has a five-year performance of %. Its 52-week range is between 0.77 and 3.63, which gives ECOR stock a 52-week price range ratio of 34.67%
electroCore Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 4.34, a price-to-sale (PS) ratio of 32.12, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -67.05%, a ROC of -77.86% and a ROE of -95.14%. The company’s profit margin is -%, its EBITDA margin is -807.40%, and its revenue ttm is $2.76 Million , which makes it $0.06 revenue per share.
Of the last four earnings reports from electroCore Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. electroCore Inc.’s next earnings report date is 13th May 2021.
The consensus rating of Wall Street analysts for electroCore Inc. is Moderate Buy (1.67), with a target price of $3.6, which is +105.70% compared to the current price. The earnings rating for electroCore Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
electroCore Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
electroCore Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.46, ATR14 : 0.28, CCI20 : -166.56, Chaikin Money Flow : -0.32, MACD : -0.17, Money Flow Index : 62.04, ROC : -12.68, RSI : 41.57, STOCH (14,3) : 29.33, STOCH RSI : 0.25, UO : 43.49, Williams %R : -70.67), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of electroCore Inc. in the last 12-months were:
electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.
CEO: Daniel S. Goldberger
Telephone: +1 973 290-0097
Address: 150 Allen Road, Basking Ridge 07920, NJ, US
Number of employees: 51
